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Abstract
Clinical Question Are different opioid agonist treatments (eg, methadone vs buprenorphine) associated with
differences in efficacy for treating prescription opioid dependence, and is long-term maintenance of opioid
agonist treatment associated with differences in efficacy compared with opioid taper or psychological
treatments alone? Bottom Line For patients who are dependent on prescription opioids, long-term
maintenance of opioid agonists is associated with less prescription opioid use and better adherence to
medication and psychological therapies for opioid dependence compared with opioid taper or psychological
treatments alone. Methadone maintenance was not associated with differences in therapeutic efficacy
compared with buprenorphine maintenance treatment. Evidence quality was low to moderate.
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Introduction
The United States is experiencing an opioid overdose epidemic, with
recent increases in prescription opioid–related mortality.1,2 Opioid ago-
nist treatment is recommended for treating prescription opioid de-
pendence by the US Centers for Disease Control and Prevention.3 This
Clinical Evidence Synopsis summarizes findings from a Cochrane re-
view that aimed to summarize current evidence for the treatment of
prescription opioid dependence using opioid agonist treatments.4
Summary of Findings
Methadone vs Buprenorphine
Three studies compared methadone with buprenorphine (Table).
No difference was found in the mean number of days of opioid use
(assessed during final 30 days of the intervention, 1.51 days [SD,
4.97 days] for methadone vs 2.92 days [SD, 6.38 days] for
buprenorphine; mean difference, −1.41 [95% CI, −3.37 to 0.55];
P = .16), opioid use as measured by opioid-positive urine drug
screening (27 of 79 participants [34.2%] for methadone vs 51 of 117
participants [43.6%] for buprenorphine; risk ratio [RR], 0.81 [95%
CI, 0.56 to 1.18]; P = .28), and self-reported opioid use (11 of 66 par-
ticipants [16.7%] for methadone vs 34 of 89 participants [38.2%]
for buprenorphine; RR, 0.37 [95% CI, 0.08 to 1.63]; P = .19). No
between-group difference was found in treatment adherence for
methadone (Table).
Buprenorphine Maintenance vs Opioid Taper
Three studies compared buprenorphine maintenance with opioid
taper or psychological treatment only. No between-group differ-
ence was found for mean days of opioid use during past 7 days or
30 days (standardized mean difference, −0.31 [95% CI, −0.66 to
0.04]; P = .08). Buprenorphine maintenance treatment was asso-
ciated with reduced opioid use as determined by urine opioid-
positive drug screening (39 of 97 participants [40.2%] vs 67 of 109
participants [61.5%] with opioid taper; RR, 0.63 [95% CI, 0.43 to
0.91]; P = .02) and reduced opioid use by self-report (37 of 100 par-
ticipants [37.0%] vs 62 of 104 participants [59.6%] with opioid
taper; RR, 0.54 [95% CI, 0.31 to 0.93]; P = .003). Buprenorphine
maintenance therapy was associated with greater treatment
adherence (83 of 110 participants [75.5%] vs 36 of 137 participants
[26.3%] with opioid taper; RR, 0.33 [95% CI, 0.23 to 0.47];
P < .001).
Discussion
No difference was found in treatment outcomes between metha-
done and buprenorphine maintenance therapy in prescription
opioid dependence treatment. Maintenance treatment was asso-
ciated with better substance use and treatment adherence out-
comes compared with shorter-term treatments. Updated searches
(conducted in August 2016) identified no additional eligible trials.
CLINICAL QUESTION Are different opioid agonist treatments (eg, methadone vs
buprenorphine) associated with differences in efficacy for treating prescription opioid
dependence, and is long-term maintenance of opioid agonist treatment associated with
differences in efficacy compared with opioid taper or psychological treatments alone?
BOTTOM LINE For patients who are dependent on prescription opioids, long-term
maintenance of opioid agonists is associated with less prescription opioid use and better
adherence to medication and psychological therapies for opioid dependence compared with
opioid taper or psychological treatments alone. Methadone maintenance was not associated
with differences in therapeutic efficacy compared with buprenorphine maintenance
treatment. Evidence quality was low to moderate.
Evidence Profile
No. of studies: 6 randomized clinical trials
Study years: Conducted: 2002-2014; published: 2003-2015
Last search date: May 13, 2015
Number of participants: 607
Men: 77% Women: 33%
Race/ethnicity: 86% white (reported in 3 studies)
Age, mean (range): 32 years (17-60 years; reported in 3 studies)
Setting: Outpatient; 1 study recruited from emergency
departments
Countries: United States and Iran
Comparisons: (1) Different opioid agonist maintenance treatments
(methadone vs buprenorphine) and (2) maintenance treatment
(buprenorphine) vs opioid taper and vs psychological
treatment alone.
Primary Outcomes: Illicit opioid use and treatment adherence
(attending counseling visits, taking prescribed medication
per protocol, or both).
Secondary Outcomes: Pain, injecting behaviors, quality of life,
physical and psychological health.
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Limitations
Most studies were conducted in the United States. No studies used
a double-blind method, and all studies had relatively small sample
sizes (53-204 participants). Due to the overall low to moderate qual-
ity of the evidence and sample sizes, it is possible further research
may change these conclusions.
Comparison of Findings With Current Practice Guidelines
The US Center for Substance Abuse Treatment guidelines5 and
A Guideline for the Clinical Management of Opioid Addiction6 sug-
gest that long-term treatment is preferable to withdrawal treat-
ment alone, consistent with the findings of this review. The Ameri-
can Society of Addiction Medicine guidelines7 concluded that
evidence supports methadone and buprenorphine maintenance,
consistent with the results of this review, and that treatment set-
ting (supervised dosing in a drug treatment clinic vs treatment pro-
vided in a physician’s office) is important when taking into account
patient preference and safety considerations.
Areas in Need of Future Study
Further research should include examining the treatment of con-
current chronic pain and opioid dependence and comparing
outcomes for psychological treatment and taper. Inclusion of vali-
dated pain measures in future studies will facilitate a better under-
standing of pain as it relates to treatment of opioid addiction. See
JAMA opioid microsite (http://sites.jamanetwork.com/opioids/) for
further clinical information such as differences between methadone
and buprenorphine induction.
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Table. Opioid Agonist Treatments for Prescription Opioid Dependence
Primary Outcomes
No. of
Studies
Range, wk Methadone Buprenorphine
Risk Ratio (95% CI)
P
Value
Quality of
the Evidence
(GRADE)b
Treatment
Duration
Total
Follow-up No.a
Total
No. No.a
Total
No.
Studies That Compared Methadone With Buprenorphine
Illicit opioid use during final 30 d
of the intervention
1 24 32 1.51
(4.97)c
53 2.92
(6.38)c
76 −1.41 (−3.37 to 0.55)d .16e Moderate
Opioid-positive urine drug screening
at treatment completion
2 24 to 26 26 to 32 27 79 51 117 0.81 (0.56 to 1.18) .28f Moderate
Self-reported substance use at end
of treatment
2 24 to 26 26 to 32 11 66 34 89 0.37 (0.08 to 1.63) .19f Moderate
Adherenceg 3 24 to 26 24 to 32 121 162 125 198 0.69 (0.39 to 1.22)h .20f Low
Studies That Compared Buprenorphine Maintenance With Opioid Taper or Psychological Treatment Only
Buprenorphine Opioid Taperi
Illicit opioid use 2 4 to 14 4 to 14 NAj 69 NAj 64 −0.31 (−0.66 to 0.04)d .08e Low
Opioid-positive urine drug screening
at treatment completion
3 4 to 14 4 to 52 39 97 67 109 0.63 (0.43 to 0.91) .02f Low
Self-reported opioid use at end
of treatment
3 4 to 14 4 to 52 37 100 62 104 0.54 (0.31 to 0.93) .003e Low
Adherenceg 3 4 to 14 4 to 52 83 110 36 137 0.33 (0.23 to 0.47)h <.001f Moderate
Abbreviations: GRADE, Grading of Recommendations, Assessment,
Development and Evaluations; NA, not available.
a Unless otherwise indicated.
b Moderate defined as moderately confident in the effect estimate (ie, true
estimate is likely to be close to the estimate of the effect, but there is a
possibility that it is substantially different); and low, confidence in the effect
estimate is limited (ie, the true effect may be substantially different from the
estimate of the effect).
c Indicates mean (SD).
d Indicates mean difference (95% CI).
e Calculated using inverse variance.
f Calculated using the Mantel-Haenszel test.
g Attended counseling visits, took prescribed medication, or both per protocol.
h The analyses represents the risk of someone being nonadherent.
i Or psychological treatment only.
j Had different denominators (ie, past 7 days or 30 days) in different studies;
therefore, the results were calculated using the standard mean difference.
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